Aeterna Zentaris Inc. announced the U.S. District Court for the District of New Jersey has given final approval of the settlement from the class-action lawsuit against the Company.
Aeterna Zentaris Inc. announced it concluded that Macrilen™ demonstrated performance supportive of achieving registration with the U.S. Food and Drug Administration.